Evidence map›Paper›PMID 14694094›Full record

ArticleJournal of virology2004

Persistent recognition of autologous virus by high-avidity CD8 T cells in chronic, progressive human immunodeficiency virus type 1 infection.

R Draenert, C L Verrill, Y Tang, T M Allen, A G Wurcel, M Boczanowski, A Lechner, A Y Kim, T Suscovich, N V Brown and 2 more

Abstract read
In one paragraph

Article in Journal of virology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed
4.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 138 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Observational
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Effects of neutralizing antibodies on escape from CD8+ T-cell responses in HIV-1 infection.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2015
    Article
  12. Review
  13. CD8+ TCR Bias and Immunodominance in HIV-1 Infection.Journal of immunology (Baltimore, Md. : 1950) · 2015
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

R DraenertHoward Hughes Medical Institute, Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School Division of AIDS, Boston, Massachusetts 02129, USA.
C L Verrill
Y Tang
T M Allen
A G Wurcel
M Boczanowski
A Lechner
A Y Kim
T Suscovich
N V Brown
M M Addo
B D Walker
Massachusetts General Hospital · USHoward Hughes Medical Institute · USLemuel Shattuck Hospital · US

Funding

Acute CTL Escape and Viral Variation in HIVR01AI054178 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2003 to 2007
$2.1M
HIV-1-SPECIFIC T CELL CLONESR01AI028568 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI WALKER, BRUCE D · 1989 to 2008
$1.9M
Impact of CTL Escape Mutations on HIV-1 Replicative FitnessR56AI054178 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALLEN, TODD M · 2009 to 2009
$442k
NIAID NIH HHS AI054178-01NIAID NIH HHS R01 AI028568NIAID NIH HHS R01 AI054178NIAID NIH HHS R01 AI28568NIAID NIH HHS R56 AI054178PHS HHS N01-A1-15442
6 · The paper itself

Abstract

CD8 T-cell responses are thought to be crucial for control of viremia in human immunodeficiency virus (HIV) infection but ultimately fail to control viremia in most infected persons. Studies in acute infection have demonstrated strong CD8-mediated selection pressure and evolution of mutations conferring escape from recognition, but the ability of CD8 T-cell responses that persist in late-stage infection to recognize viruses present in vivo has not been determined. Therefore, we studied 24 subjects with advanced HIV disease (median viral load = 142,000 copies/ml; median CD4 count = 71/ micro l) and determined HIV-1-specific CD8 T-cell responses to all expressed viral proteins using overlapping peptides by gamma interferon Elispot assay. Chronic-stage virus was sequenced to evaluate autologous sequences within Gag epitopes, and functional avidity of detected responses was determined. In these subjects, the median number of epitopic regions targeted was 13 (range, 2 to 39) and the median cumulative magnitude of CD8 T-cell responses was 5,760 spot-forming cells/10(6) peripheral blood mononuclear cells (range, 185 to 24,700). On average six (range, one to 8) proteins were targeted. For 89% of evaluated CD8 T-cell responses, the autologous viral sequence was predicted to be well recognized by these responses and the majority of analyzed optimal epitopes were recognized with medium to high functional avidity by the contemporary CD8 T cells. Withdrawal of antigen by highly active antiretroviral therapy led to a significant decline both in breadth (P = 0.032) and magnitude (P = 0.0098) of these CD8 T-cell responses, providing further evidence that these responses had been driven by recognition of autologous virus. These results indicate that strong, broadly directed, and high-avidity gamma-interferon-positive CD8 T-cells directed at autologous virus persist in late disease stages, and the absence of mutations within viral epitopes indicates a lack of strong selection pressure mediated by these responses. These data imply functional impairment of CD8 T-cell responses in late-stage infection that may not be reflected by gamma interferon-based screening techniques.

Indexed as

Amino Acid SequenceCD8-Positive T-LymphocytesChronic DiseaseDisease ProgressionEpitopes, T-LymphocyteGene Products, gagHIV-1HIV InfectionsHumansInterferon-gammaMolecular Sequence DataPeptidesViral ProteinsEpitopes, T-LymphocyteGene Products, gagInterferon-gammaPeptidesViral Proteins

Identifiers

PMID14694094
PMCPMC368768
OpenAlexW2081844025

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.